Free Trial
LON:INDV

Indivior (INDV) Share Price, News & Analysis

GBX 775
-19.00 (-2.39%)
(As of 12:01 PM ET)
Today's Range
771.35
807.75
50-Day Range
756.50
1,230
52-Week Range
653
1,877.20
Volume
58.79 million shs
Average Volume
1.38 million shs
Market Capitalization
£1.02 billion
P/E Ratio
N/A
Dividend Yield
1.94%
Price Target
GBX 1,500

Indivior MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
93.5% Upside
GBX 1,500 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.26mentions of Indivior in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
£1.50 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

INDV stock logo

About Indivior Stock (LON:INDV)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

INDV Stock Price History

INDV Stock News Headlines

How Boeing Disasters Could Impact Nvidia
How The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart midflight and catching fire. But, according to analyst Dan Ferris, there's something much darker going on here that could threaten Nvidia, the Magnificent 7, and the entire U.S. stock market.
Indivior (LON:INDV) Stock Price Down 7.9%
Deutsche Bank Sticks to Their Buy Rating for Indivior (INDV)
How Boeing Disasters Could Impact Nvidia
How The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart midflight and catching fire. But, according to analyst Dan Ferris, there's something much darker going on here that could threaten Nvidia, the Magnificent 7, and the entire U.S. stock market.
Hypera S.A. (HM6A.F)
See More Headlines
Receive INDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
1,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 1,500
High Stock Price Target
GBX 1,500
Low Stock Price Target
GBX 1,500
Potential Upside/Downside
+89.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£-141,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.15 billion
Cash Flow
GBX 295.70 per share
Book Value
GBX (90) per share

Miscellaneous

Free Float
N/A
Market Cap
£1.04 billion
Optionable
Not Optionable
Beta
0.17
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark Crossley
    CEO & Executive Director
  • Mr. Ryan Preblick
    CFO & Executive Director
  • Dr. Christian Heidbreder
    Chief Scientific Officer
  • Mr. Jason Thompson
    Vice President of Investor Relations
  • Ms. Cynthia Cetani
    Chief Integrity & Compliance Officer
  • Mr. Jeffrey W. Burris (Age 52)
    Chief Legal Officer
  • Mr. Jon Fogle
    Chief Human Resources Officer
  • Mr. Richard Simkin
    Chief Commercial Officer
  • Mr. Hillel West
    Chief Manufacturing & Supply Officer
  • Mr. Vishal Kalia
    SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer

INDV Stock Analysis - Frequently Asked Questions

How have INDV shares performed this year?

Indivior's stock was trading at GBX 1,185 at the start of the year. Since then, INDV shares have decreased by 34.6% and is now trading at GBX 775.
View the best growth stocks for 2024 here
.

How do I buy shares of Indivior?

Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK) and Bodycote (BOY).

This page (LON:INDV) was last updated on 9/9/2024 by MarketBeat.com Staff

From Our Partners